Quick Answer
CG Oncology, Inc. reported R&D Expense of $116.64 million for fiscal year 2025.
CG Oncology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $116.64M | +42.1% |
| 2024 | $82.10M | +79.5% |
| 2023 | $45.75M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $27.88M | +42.1% | -11.0% |
| June 30, 2025 | $31.33M | +69.6% | +14.1% |
| March 31, 2025 | $27.47M | +59.6% | +40.0% |
| September 30, 2024 | $19.62M | +67.2% | +6.2% |
| June 30, 2024 | $18.47M | +87.9% | +7.3% |
| March 31, 2024 | $17.21M | +119.5% | +46.7% |
| September 30, 2023 | $11.73M | — | +19.4% |
| June 30, 2023 | $9.83M | — | +25.4% |
- CG Oncology, Inc. showed an increase of +42.1% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, CG Oncology, Inc.’s r&d expense has grown by 154.9% (from $45.75 million to $116.64 million).
- The most recent figure is from CG Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: